Adaptimmune Therapeutics (NASDAQ:ADAP) Releases Quarterly Earnings Results, Misses Estimates By $0.09 EPS

Adaptimmune Therapeutics (NASDAQ:ADAP) issued its quarterly earnings data on Monday. The biotechnology company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.09), Zacks reports. Adaptimmune Therapeutics had a negative return on equity of 74.15% and a negative net margin of 25.43%.

Adaptimmune Therapeutics Trading Down 4.8 %

NASDAQ:ADAP traded down $0.01 on Monday, reaching $0.28. 2,891,768 shares of the stock traded hands, compared to its average volume of 1,687,464. The firm has a market capitalization of $70.83 million, a price-to-earnings ratio of -1.26 and a beta of 2.52. Adaptimmune Therapeutics has a 1-year low of $0.26 and a 1-year high of $1.65. The company has a current ratio of 3.85, a quick ratio of 3.82 and a debt-to-equity ratio of 0.62. The company’s 50 day moving average is $0.54 and its 200-day moving average is $0.69.

Analysts Set New Price Targets

A number of research analysts recently commented on ADAP shares. Scotiabank reduced their target price on Adaptimmune Therapeutics from $3.15 to $1.40 and set a “sector outperform” rating on the stock in a report on Friday. StockNews.com assumed coverage on shares of Adaptimmune Therapeutics in a research note on Friday. They issued a “buy” rating for the company. Mizuho decreased their target price on shares of Adaptimmune Therapeutics from $3.00 to $1.50 and set an “outperform” rating on the stock in a research note on Wednesday, November 27th. Finally, Wells Fargo & Company lowered their price target on shares of Adaptimmune Therapeutics from $2.00 to $1.50 and set an “equal weight” rating for the company in a report on Friday. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $2.18.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.